A 58-year-old woman with a 10-year history of type 2 diabetes mellitus presents with progressive edema, dyspnea, and a 3 kg weight gain over 2 weeks. Blood pressure is 142/92 mmHg. Serum creatinine is 2.8 mg/dL (eGFR 22 mL/min/1.73 m²), and urinary albumin-to-creatinine ratio is 380 mg/g. Serum potassium is 5.8 mEq/L. She is not on any ACE inhibitor or ARB. Which of the following best explains the hyperkalemia in the context of her declining renal function and RAAS physiology?

Explanation

## Clinical Context This patient has **diabetic nephropathy** with advanced chronic kidney disease (CKD stage 3b). The combination of declining renal function, volume expansion (edema, weight gain), and hyperkalemia reflects both reduced GFR and impaired aldosterone-mediated potassium excretion. ## Mechanism of Hyperkalemia in CKD **Key Point:** Hyperkalemia in CKD results primarily from **impaired distal potassium secretion**, not reduced filtration. The collecting duct is the major site of potassium excretion, and this depends on aldosterone and the driving force for K^+^ secretion. ### Why Aldosterone is Suppressed in This Patient Despite declining renal function, aldosterone is often **suppressed or inappropriately low** in CKD because: 1. **Volume expansion** from sodium and fluid retention → increased renal perfusion pressure 2. **Suppressed renin activity** via macula densa feedback (increased distal sodium delivery) 3. **Reduced Ang II formation** → decreased aldosterone stimulation 4. **Direct renal effects** of hyperkalemia and acidosis may also suppress aldosterone This is paradoxical: the kidney cannot excrete potassium effectively, yet aldosterone (which promotes K^+^ secretion) is suppressed. ### Potassium Secretion in the Collecting Duct ```mermaid flowchart TD A[Aldosterone binds mineralocorticoid receptor]:::action --> B[Increases ENaC expression in collecting duct]:::action B --> C[Increased Na+ reabsorption]:::action C --> D[Negative lumen potential]:::outcome D --> E[Increased K+ secretion gradient]:::outcome F[Reduced aldosterone] -->|Decreases ENaC| G[Reduced Na+ reabsorption]:::action G --> H[Less negative lumen potential]:::outcome H --> I[Reduced K+ secretion]:::urgent I --> J[Hyperkalemia]:::urgent ``` **High-Yield:** The mechanism of hyperkalemia in CKD: - **Reduced GFR** accounts for ~20–30% of potassium retention - **Reduced aldosterone-mediated K^+^ secretion** accounts for ~70–80% - ENaC activity is the rate-limiting step for distal K^+^ secretion ## Why This Patient Has Suppressed Aldosterone Despite Hyperkalemia | Factor | Effect on Aldosterone | |--------|----------------------| | **Volume expansion** | ↓ (suppresses renin) | | **Hyperkalemia** | ↑ (should stimulate) | | **Acidosis** | ↓ (suppresses) | | **Net effect in CKD** | ↓ (volume effect dominates) | **Clinical Pearl:** In CKD, the **volume-mediated suppression of renin** often overwhelms the direct stimulatory effect of hyperkalemia on aldosterone secretion. This creates a vicious cycle: the kidney cannot excrete potassium because aldosterone is suppressed, yet potassium accumulates because GFR is low. **Mnemonic:** **RAAS Paradox in CKD** — **R**educed renin (volume expansion) → **A**ldosterone suppressed → **A**ccumulation of potassium → **S**evere hyperkalemia.